miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway

Oncotarget

Volumn 6, Issue 6, 2015, Pages 3988-4004

  Xu, Xinsen ^a   Chen, Wei ^a   Miao, Runchen ^a   Zhou, Yanyan ^a   Wang, Zhixin ^a   Zhang, Lingqiang ^a   Wan, Yong ^a   Dong, Yafeng ^b   Qu, Kai ^a   Liu, Chang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

HCC; miR 34a; Senescence; Telomerase; Telomere

Indexed keywords

MICRORNA 34A; MYC PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; CISPLATIN; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; HYDROGEN PEROXIDE; MICRORNA; MIRN34 MICRORNA, HUMAN; MYC PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL AGING; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FOXM1 GENE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSCRIPTION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PHENOTYPE; SIGNAL TRANSDUCTION; TELOMERE; ANIMAL; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG SCREENING; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LENTIVIRINAE; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL AGING; CELL LINE, TUMOR; CISPLATIN; FEMALE; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTORS; GENETIC VECTORS; HEP G2 CELLS; HUMANS; HYDROGEN PEROXIDE; LENTIVIRUS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; TELOMERASE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924252998     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2905     Document Type: Article

References (41)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
2. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: a cancer journal for clinicians. 2012; 62:394-399.
3. Menard L, Taras D, Grigoletto A, Haurie V, Nicou A, Dugot-Senant N, Costet P, Rousseau B, Rosenbaum J. In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence. Journal of hepatology. 2010; 52:681-689.
4. Senturk S, Mumcuoglu M, Gursoy-Yuzugullu O, Cingoz B, Akcali KC, Ozturk M. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology. 2010; 52:966-974.
5. Qu K, Xu X, Liu C, Wu Q, Wei J, Meng F, Zhou L, Wang Z, Lei L, Liu P. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma. Cancer letters. 2013; 331:105-114.
6. Qu K, Lin T, Wang Z, Liu S, Chang H, Xu X, Meng F, Zhou L, Wei J, Tai M, Dong Y, Liu C. Reactive oxygen species generation is essential for cisplatininduced accelerated senescence in hepatocellular carcinoma. Frontiers of medicine. 2014; 8:227-235.
7. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007; 130:223-233.
8. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP, Rudolph KL. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2002; 16:935-942.
9. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Ide T, Ishikawa F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nature genetics. 1998; 18:65-68.
10. Sharpless NE DePinho RA. Telomeres, stem cells, senescence, and cancer. Journal of Clinical Investigation. 2004; 113:160.
11. Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, Kubicka S, Schirmacher P, Jonkers J, Rudolph KL. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology. 2007; 132:1465-1475.
12. Williams SC. No end in sight for telomerase-targeted cancer drugs. Nature medicine. 2013; 19:6-6.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
14. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics. 2009; 10:704-714.
15. Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu N. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer science. 2008; 99:280-286.
16. Chen L, Lü M, Zhang D, Hao N, Fan Y, Wu Y, Wang S, Xie R, Fang D, Zhang H. miR-1207-p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death & Disease. 2014; 5:e1034.
17. Tzfati Y, Chensny L, Benos P, Kaminski N, Singh M. Regulation Telomerase and Telomere Length In IPF By MicroRNAs. Am J Respir Crit Care Med. 2010; 181:A2297.
18. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447:1130-1134.
19. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer letters. 2009; 275:44-53.
20. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene. 2012; 498:135-146.
21. Wierstra I, Alves J. FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2. The FEBS journal. 2006; 273:4645-4667.
22. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer. 2006; 6:857-866.
23. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumorsuppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:15472-15477.
24. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007; 26:5017-5022.
25. Tryndyak VP, Ross SA, Beland FA, Pogribny IP. Downregulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Molecular carcinogenesis. 2009; 48:479-487.
26. Sukata T, Sumida K, Kushida M, Ogata K, Miyata K, Yabushita S, Uwagawa S. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicology letters. 2011; 200:46-52.
27. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, Maris JM. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Molecular cancer research: MCR. 2008; 6:735-742.
28. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J, Harris CC. Nutlin-3a activates p53 to both downregulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer research. 2008; 68:3193-3203.
29. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell death and differentiation. 2010; 17:236-245.
30. Bai XY, Ma Y, Ding R, Fu B, Shi S, Chen XM. miR-335 and miR-34a Promote renal senescence by suppressing mitochondrial antioxidative enzymes. Journal of the American Society of Nephrology: JASN. 2011; 22:1252-1261.
31. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Current biology: CB. 2007; 17:1298-1307.
32. Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. Journal of biochemical and molecular toxicology. 2012; 26:79-86.
33. Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao H, Li C, Chen Y, Zhao J. miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:1503-1510.
34. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nature genetics. 1999; 21:220-224.
35. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997; 277:955-959.
36. Zeng J, Wang L, Li Q, Li W, Bjorkholm M, Jia J, Xu D. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. The Journal of pathology. 2009; 218:419-427.
37. Ozturk M, Arslan-Ergul A, Bagislar S, Senturk S, Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. Cancer letters. 2009; 286:103-113.
38. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. Genomic targets of the human c-Myc protein. Genes & development. 2003; 17:1115-1129.
39. Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, Moore DD, Trumpp A. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology. 2008; 48:1302-1311.
40. Zhang Y, Sturgis EM, Dahlstrom KR, Wen J, Liu H, Wei Q, Li G, Liu Z. Telomere length in peripheral blood lymphocytes contributes to the development of HPVassociated oropharyngeal carcinoma. Cancer research. 2013; 73:5996-6003.
41. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer research. 2002; 62:1876-1883.